← Leaderboards
Robert M Caudle
University Of Florida
$7,021,665
Attributed
$16,891,210
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,891,210 · 8
By mechanism
UC2$10,388,769 · 1
R01$4,918,856 · 2
R21$1,058,923 · 3
R43$390,335 · 1
R03$134,327 · 1
Top collaborators
- John K Neubert9 shared
- Kyle D Allen4 shared
- Alejandro Jose Almarza4 shared
- Yenisel Cruz-Almeida2 shared
- Basak Ayaz1 shared
- Craig Friedman1 shared
Most similar at University Of Florida
Same institution · by research overlap
- John K Neubert$3,553,315
- Yenisel Cruz-Almeida$13,117,222
- Paul R Carney$38,125
- Basak Ayaz$419,375
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainChronic PainChronicVariantRattusPain ManagementOpioid ReceptorPain MeasurementBehavioralBehaviorPharmaceutical PreparationsNovel StrategiesOpioidAnalgesicsCostMapsAnimalsSocietiesAffectAbsence Of Pain SensationPain ModelMotorNeuronsClinically Relevant
Grant awards (27)
Innervation of the knee and TMJ$3,781,916
UC2 · FY2025 · AR
Opioid and cannabinoid interactions in pain and reward$615,440
R01 · FY2024 · DA · contact PI
Role of Understudied aGPCRs in Orofacial Neuropathic Pain$419,375
R21 · FY2024 · DE · contact PI
Opioid and cannabinoid interactions in pain and reward$100,000
R01 · FY2024 · DA
Opioid and cannabinoid interactions in pain and reward$615,440
R01 · FY2023 · DA
Evaluating the role of fascia structure and innervation in chronic knee OA pain$510,381
UC2 · FY2023 · AR
Diversity Supplement_Folly Patterson$217,476
UC2 · FY2023 · AR
Kinetics and target engagement for a Phase II trial of RTX for cancer pain$100,000
R01 · FY2023 · DA
Innervation of the knee and TMJ$5,878,996
UC2 · FY2022 · AR
Opioid and cannabinoid interactions in pain and reward$615,440
R01 · FY2022 · DA
Opioid and cannabinoid interactions in pain and reward$95,168
R01 · FY2022 · DA
Opioid and cannabinoid interactions in pain and reward$615,440
R01 · FY2021 · DA
Opioid and cannabinoid interactions in pain and reward$95,168
R01 · FY2021 · DA
Opioid and cannabinoid interactions in pain and reward$615,440
R01 · FY2020 · DA
Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes$390,335
R43 · FY2019 · DE
Morphine induced alterations in NMDA receptor subunit expression$177,631
R21 · FY2011 · DA · contact PI
Morphine induced alterations in NMDA receptor subunit expression$171,500
R21 · FY2010 · DA · contact PI
Dynorphin Modulation of N-Methyl-D-Aspartate (NMDA) Receptor Function$252,011
R01 · FY2009 · NS · contact PI
Dynorphin Modulation of N-Methyl-D-Aspartate (NMDA) Receptor Function$252,431
R01 · FY2008 · NS · contact PI
Dynorphin Modulation of N-Methyl-D-Aspartate (NMDA) Receptor Function$292,666
R01 · FY2007 · NS · contact PI
Dynorphin Modulation of N-Methyl-D-Aspartate (NMDA) Receptor Function$300,343
R01 · FY2006 · NS · contact PI
Dynorphin Modulation of N-Methyl-D-Aspartate (NMDA) Receptor Function$38,910
R01 · FY2006 · NS · contact PI
Dynorphin Modulation of N-Methyl-D-Aspartate (NMDA) Receptor Function$314,959
R01 · FY2005 · NS
Targeted Cholera Toxin for Treatment of Hyperalgesia$145,417
R21 · FY2004 · DA
Targeted Cholera Toxin for Treatment of Hyperalgesia$145,000
R21 · FY2003 · DA
NOCICEPTION AND NMDA RECEPTOR PHOSPHORYLATION$67,417
R03 · FY2001 · DA
NOCICEPTION AND NMDA RECEPTOR PHOSPHORYLATION$66,910
R03 · FY2000 · DA